Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Marex Group initiates coverage of NFL Biosciences with a Buy rating

Company: NFL Biosciences Date: 2025-04-24 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

## **Press release**

# **Marex Group initiates coverage of NFL Biosciences with a Buy rating**

**Montpellier, France, April 24, 2025, at 5:45 p.m. CEST** – **NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL),** a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announces that Marex Group has initiated analyst coverage of its stock.

Marex Group initiated coverage today with a Buy recommendation and a price target of €3.60. The analyst's investment case is based on three key drivers:

- Validation of the Phase III clinical trial, representing a major milestone in the development of NFL-101;
- Potential pharma partnerships around NFL-101, which could lead to licensing agreements or codevelopment collaborations;
- Speculative upside linked to a potential acquisition of NFL Biosciences by a Big Pharma upon successful completion of the Phase III program.

Headquartered in London, Marex Group operates through more than 40 offices worldwide, offering clearing, agency and execution, market making, hedging, and investment solutions services.

NFL Biosciences is also covered by Invest Securities and Portzamparc (Groupe BNP Paribas).

### **About NFL Biosciences:** [www.nflbiosciences.com](http://www.nflbiosciences.com/)

NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easyto-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.

NFL Biosciences shares are listed on Euronext Paris (FR0014003XT0 - ALNFL).

### **Contacts:**

Investor Relations / Media Relations Mathilde Bohin / Arthur Rouillé Tel: +33 (0)1 44 71 94 94 E-mail[: nfl@newcap.eu](file:///C:/Users/Newcap/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/39PWNFVK/nfl@newcap.eu)

#### **NewCap NFL Biosciences**

Bruno Lafont Tel: +33 (0)4 11 93 76 67 E-mail: [info@nflbiosciences.com](mailto:info@nflbiosciences.com)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now